Semaglutide—sold as Ozempic for type 2 diabetes and as Wegovy for weight loss—may help prevent heart attacks and strokes.

Researchers randomly assigned 17,604 people aged 45 or older with excess weight to a weekly injection of semaglutide (2.4 milligrams) or a placebo. All had either had an earlier heart attack or stroke or had symptomatic peripheral arterial disease, but not diabetes. The trial was funded by semaglutide’s maker, Novo Nordisk.

After roughly three years, those assigned to semaglutide had a 20 percent lower risk of a cardiovascular event (mostly a heart attack or stroke) than those who got the placebo. And weight, blood pressure, LDL cholesterol, and blood sugar levels fell more in the semaglutide takers.

What to do

Got excess weight and cardiovascular risk? Ask your doctor about semaglutide. In earlier studies, it also cut those risks in people with type 2 diabetes.

tangerines in front of a fruit bowl

Subscribe to Nutrition Action

We name names, remain strictly objective, and deliver scrupulously researched advice about food of all kinds, staying healthy with diet and exercise, and more.

Sign up today